JP2016535009A5 - - Google Patents

Download PDF

Info

Publication number
JP2016535009A5
JP2016535009A5 JP2016524060A JP2016524060A JP2016535009A5 JP 2016535009 A5 JP2016535009 A5 JP 2016535009A5 JP 2016524060 A JP2016524060 A JP 2016524060A JP 2016524060 A JP2016524060 A JP 2016524060A JP 2016535009 A5 JP2016535009 A5 JP 2016535009A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
exosome
cells
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061245 external-priority patent/WO2015058148A1/en
Publication of JP2016535009A publication Critical patent/JP2016535009A/ja
Publication of JP2016535009A5 publication Critical patent/JP2016535009A5/ja
Pending legal-status Critical Current

Links

JP2016524060A 2013-10-17 2014-10-17 抗体依存性エキソソーム治療の方法 Pending JP2016535009A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361892352P 2013-10-17 2013-10-17
US61/892,352 2013-10-17
US201462038734P 2014-08-18 2014-08-18
US62/038,734 2014-08-18
PCT/US2014/061245 WO2015058148A1 (en) 2013-10-17 2014-10-17 Antibody dependent exosome therapy

Publications (2)

Publication Number Publication Date
JP2016535009A JP2016535009A (ja) 2016-11-10
JP2016535009A5 true JP2016535009A5 (enExample) 2017-11-09

Family

ID=52828772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524060A Pending JP2016535009A (ja) 2013-10-17 2014-10-17 抗体依存性エキソソーム治療の方法

Country Status (4)

Country Link
US (1) US20160243192A1 (enExample)
EP (1) EP3057662A4 (enExample)
JP (1) JP2016535009A (enExample)
WO (1) WO2015058148A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
WO2015157652A1 (en) 2014-04-11 2015-10-15 University Of Louisville Research Foundation, Inc. Coated edible plant-derived microvesicle compositions and methods for using the same
CN107920995A (zh) * 2015-07-02 2018-04-17 路易斯威尔大学研究基金会 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法
NZ742327A (en) 2015-11-18 2020-01-31 Aruna Biomedical Inc Neural cell extracellular vessicles
EP3377043A4 (en) 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
CN110662532A (zh) 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
US10815520B2 (en) 2017-04-07 2020-10-27 University Of Louisville Research Foundation, Inc. Nanovesicles, methods, and systems for diagnosis and prognosis of cancer
EP3438250B1 (en) 2017-07-31 2022-12-07 Rheinische Friedrich-Wilhelms-Universität Bonn Cell derived extracellular vesicles for the treatment of diseases
US12036262B2 (en) 2017-11-22 2024-07-16 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
CN110613728B (zh) * 2017-12-11 2022-06-21 浙江大学 NK细胞外泌体hsa-miR-9773在抗菌中的应用
EP3752615B1 (en) * 2018-02-12 2025-08-27 Lonza Sales AG Methods and compositions for macrophage polarization
IL266153A (en) * 2019-04-18 2019-07-31 Aharon Anat Extracellular vesicles derived from t cells containing a chimeric antigen receptor
US12357704B2 (en) 2019-05-06 2025-07-15 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247610A1 (en) 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
US20210130782A1 (en) * 2019-10-28 2021-05-06 Augusta University Research Institute, Inc. Engineered Exosomes to Detect and Deplete Pro-Tumorigenic Macrophages
CN115942957A (zh) * 2019-11-04 2023-04-07 阿鲁纳生物股份公司 细胞外囊泡及其用于抗体递送的用途
CN111450249A (zh) * 2020-03-09 2020-07-28 杨静悦 miRNA-320a的表达促进物在制备抑制肿瘤细胞药物中的应用
JP2023536665A (ja) * 2020-08-05 2023-08-28 オハイオ・ステイト・イノベーション・ファウンデーション アダプターポリペプチドおよびその使用方法
WO2022149779A1 (ko) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
WO2022158836A1 (ko) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
US20230144704A1 (en) * 2021-11-05 2023-05-11 Thomas Malcolm Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
CN115887491B (zh) * 2022-11-10 2026-07-28 中国药科大学 一种具有骨髓靶向功能的工程化双特异性外泌体/囊泡制剂及其制备方法和应用
US20240318185A1 (en) * 2023-03-20 2024-09-26 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived microribonucleic acid-mediated treatments for the prevention and targeted treatment of cancer and other disorders
US20250170174A1 (en) * 2023-11-29 2025-05-29 Mor Research Applications Ltd. Methods of treating leukemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417229B1 (en) * 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
IL161899A0 (en) * 2004-05-10 2005-11-20 Hoffman Arnold Kit for treatment of cancer
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease

Similar Documents

Publication Publication Date Title
Ortiz et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications
Li et al. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Yin et al. Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy
Vanmeerbeek et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Sharma et al. Dendrimer-mediated targeted delivery of rapamycin to tumor-associated macrophages improves systemic treatment of glioblastoma
AU2018352221B2 (en) Peptides and nanoparticles for intracellular delivery of mRNA
AU2016251415B2 (en) C/EBP alpha saRNA compositions and methods of use
JP6731405B2 (ja) ウイルス粒子を用いた癌免疫療法
CN108392633B (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
JP2019504105A5 (enExample)
JP2019506862A5 (enExample)
JP2022092001A (ja) 樹状細胞免疫療法
JP2017518302A5 (enExample)
JP2012196206A5 (enExample)
KR20150080592A (ko) Tec 패밀리 키나제 억제제 애쥬번트 요법
Ranji et al. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance
RU2017126610A (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
EA201100586A1 (ru) Новая иммунотерапия против нескольких видов опухолей, включая нейрональные опухоли и опухоли головного мозга
US12516318B2 (en) Targeting glioblastoma stem cells through the TLX-TET3 axis
WO2019143948A1 (en) Altering inflammatory states of immune cells in vivo by modulating cellular activation states
JP2015505843A5 (enExample)
Carew et al. Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
JP2017514800A5 (enExample)
Wang et al. Current development of glioblastoma therapeutic agents
JP2019531293A5 (enExample)